<DOC>
	<DOCNO>NCT00148018</DOCNO>
	<brief_summary>The primary objective study evaluate wether bortezomib dexamethasone active patient relapse Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study Bortezomib ( Velcade ) Combination With Dexamethasone Treat Patients With Relapsed Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The proteasome-inhibitor bortezomib ( Velcade ) show promise activity various human lymphoma cell line . In addition , several study heavily pretreated patient lymphoma show also promise result .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Hodgkin 's lymphoma Second high relapse ( first relapse highdose chemotherapy possible ) Age &gt; /= 18 year No major organ dysfunction intercurrent disorder Written inform consent Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Hodgkin disease</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Relapse</keyword>
	<keyword>Lymphoma</keyword>
</DOC>